HealthyNCT06034158
Molecular Basis of Loss Aversion
A study of Healthy, run by Sir Run Run Shaw Hospital at 1 site in China.
Trial summary
The goal of this clinical trial is to test the roles of dopamine and norepinephrine in decision making related to loss aversion in the healthy population. The main question it aims to answer is whether temporarily boosting dopamine activity or temporarily suppressing norepinephrine activity has an impact on processing… Read more about this study
- Who is it for?
- Ages 25 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- 18 Sep 2023to 1 Sep 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 25-40 years old (including boundary value).
- Elementary school education or above, able to understand the research content.
- Body temperature, blood pressure, heart rate, respiratory rate, and electrocardiogram are all normal. Among them, the blood pressure range is 100-139/70-89 mmHg, and the heart rate range is 60-85 beats/min.
Who cannot join
- Vulnerable groups, including people with mental illness, cognitive impairment, critically ill subjects, minors, pregnant women, illiterates, etc.
- Family history of genetic diseases.
- Major physical diseases, including cardiovascular, respiratory, digestive, renal, endocrine, blood and other systemic diseases.
- History of alcohol/drug dependence.
- Lactating women.
- The cardiopulmonary function test results are poor.
- Have ever taken madopar or propranolol for medical use.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, 360000
Jinsong Tang, 13627311963, tangliaoyanhui@163.com
About this study
The goal of this clinical trial is to test the roles of dopamine and norepinephrine in decision making related to loss aversion in the healthy population. The main question it aims to answer is whether temporarily boosting dopamine activity or temporarily suppressing norepinephrine activity has an impact on processing of potential gains and losses in financial decision making, social decision making, transaction decision making and moral decision making. Accordingly, participants will complete four decision-making tasks, namely investment task, driving task, trading task, and die task, after taking madopar, propranolol or placebo. Participants' psychological traits and psychiatric symptoms will be assessed once they are enrolled before the first-session day.
- Conditions
- Healthy
- Being tested
- single-dose madopar, single-dose propranolol, and single-dose placebo by order, single-dose madopar, single-dose placebo, and single-dose propranolol by order, single-dose propranolol, single-dose madopar, and single-dose placebo by order, single-dose propranolol, single-dose placebo, and single-dose madopar by order, single-dose placebo, single-dose propranolol, and single-dose madopar by order
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
single-dose madopar, single-dose propranolol, and single-dose placebo by orderDrug
Participants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
single-dose madopar, single-dose placebo, and single-dose propranolol by orderDrug
Participants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
single-dose propranolol, single-dose madopar, and single-dose placebo by orderDrug
Participants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days.
single-dose propranolol, single-dose placebo, and single-dose madopar by orderDrug
Participants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
single-dose placebo, single-dose propranolol, and single-dose madopar by orderDrug
Participants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days.
single-dose placebo, single-dose madopar, and single-dose propranolol by orderDrug
Participants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days.
| Study group | Role | What they receive |
|---|---|---|
| madopar-propranolol-placebo | Other | In a within-subjects design, participants will take madopar, propranolol, and placebo each once in three separate sessions. Receives: Drug: single-dose madopar, single-dose propranolol, and single-dose placebo by order |
| madopar-placebo-propranolol | Other | In a within-subjects design, participants will take madopar, placebo, and propranolol each once in three separate sessions. Receives: Drug: single-dose madopar, single-dose placebo, and single-dose propranolol by order |
| propranolol-madopar-placebo | Other | In a within-subjects design, participants will take propranolol, madopar, and placebo each once in three separate sessions. Receives: Drug: single-dose propranolol, single-dose madopar, and single-dose placebo by order |
| propranolol-placebo-madopar | Other | In a within-subjects design, participants will take propranolol, placebo, and madopar each once in three separate sessions. Receives: Drug: single-dose propranolol, single-dose placebo, and single-dose madopar by order |
| placebo-propranolol-madopar | Other | In a within-subjects design, participants will take placebo, propranolol, and madopar each once in three separate sessions. Receives: Drug: single-dose placebo, single-dose propranolol, and single-dose madopar by order |
| placebo-madopar-propranolol | Other | In a within-subjects design, participants will take placebo, madopar, and propranolol each once in three separate sessions. Receives: Drug: single-dose placebo, single-dose madopar, and single-dose propranolol by order |
What is being measured
The primary outcome is the main question the study is designed to answer.
Choices to invest or not in the investment task
Participants decide whether or not to accept investment options that entail a 50/50 chance of winning some amount of money and losing some amount of money.
Measured: between 1-2 hours after taking the drugs or the placebo
Response times to invest or not in the investment task
Participants decide whether or not to accept investment options that entail a 50/50 chance of winning some amount of money and losing some amount of money.
Measured: between 1-2 hours after taking the drugs or the placebo
Choices to turn or not in the driving task
Participants decide whether or not to make turns during driving in order to sacrifice some number of person(s) to save some number of person(s) .
Measured: between 1-2 hours after taking the drugs or the placebo
Response times to turn or not in the driving task
Participants decide whether or not to make turns during driving in order to sacrifice some number of person(s) to save some number of person(s) .
Measured: between 1-2 hours after taking the drugs or the placebo
Choices to buy or sell in the trading task
Participants decide whether or not to buy or sell a product at certain prices.
Measured: between 1-2 hours after taking the drugs or the placebo
Response times to buy or sell in the trading task
Participants decide whether or not to buy or sell a product at certain prices.
Measured: between 1-2 hours after taking the drugs or the placebo
Reported outcomes in die task
Participants report the outcome for each throw of the die.
Measured: between 1-2 hours after taking the drugs or the placebo
Secondary outcomes (1)
Affects
Participants' affects will be assessed using the Positive and Negative Affective Scale (PANAS).Scores can range from 10 to 50 for both the Positive and Negative Affect, with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect.
Measured: before and 1 hour after taking the drugs or the placebo
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Sep 2023
- Study start18 Sep 2023
- Primary completion1 Mar 2024 (estimated)
- Study completion1 Sep 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Sir Run Run Shaw HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sir Run Run Shaw Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jinsong Tang, Sir Run Run Shaw Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06034158
- Sponsor's protocol ID
- 20230496
- Status last verified
- Sep 2023
- First submitted
- 5 Sep 2023
- Last updated
- 26 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sheng F, Ramakrishnan A, Seok D, Zhao WJ, Thelaus S, Cen P, Platt ML. Decomposing loss aversion from gaze allocation and pupil dilation. Proc Natl Acad Sci U S A. 2020 May 26;117(21):11356-11363. doi: 10.1073/pnas.1919670117. Epub 2020 May 8.
PubMed 32385152
Study at a glance
From the registry record, last updated by the sponsor on 26 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Molecular Basis of Loss Aversion
- ClinicalTrials.gov ID
- NCT06034158
- Acronym / sponsor ID
- 20230496
- Conditions
- Healthy
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Sir Run Run Shaw HospitalUniversity, hospital or other
- Study start
- 18 Sep 2023 (actual)
- Primary completion
- 1 Mar 2024 (estimated)
- Study completion
- 1 Sep 2024 (estimated)
- First posted
- 13 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to test the roles of dopamine and norepinephrine in decision making related to loss aversion in the healthy population. The main question it aims to answer is whether temporarily boosting dopamine activity or temporarily suppressing norepinephrine activity has an impact on processing of potential gains and losses in financial decision making, social decision making, transaction decision making and moral decision making. Accordingly, participants will complete four decision-making tasks, namely investment task, driving task, trading task, and die task, after taking madopar, propranolol or placebo. Participants' psychological traits and psychiatric symptoms will be assessed once they are enrolled before the first-session day.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| madopar-propranolol-placebo | Other | Drug: single-dose madopar, single-dose propranolol, and single-dose placebo by orderIn a within-subjects design, participants will take madopar, propranolol, and placebo each once in three separate sessions. |
| madopar-placebo-propranolol | Other | Drug: single-dose madopar, single-dose placebo, and single-dose propranolol by orderIn a within-subjects design, participants will take madopar, placebo, and propranolol each once in three separate sessions. |
| propranolol-madopar-placebo | Other | Drug: single-dose propranolol, single-dose madopar, and single-dose placebo by orderIn a within-subjects design, participants will take propranolol, madopar, and placebo each once in three separate sessions. |
| propranolol-placebo-madopar | Other | Drug: single-dose propranolol, single-dose placebo, and single-dose madopar by orderIn a within-subjects design, participants will take propranolol, placebo, and madopar each once in three separate sessions. |
| placebo-propranolol-madopar | Other | Drug: single-dose placebo, single-dose propranolol, and single-dose madopar by orderIn a within-subjects design, participants will take placebo, propranolol, and madopar each once in three separate sessions. |
| placebo-madopar-propranolol | Other | Drug: single-dose placebo, single-dose madopar, and single-dose propranolol by orderIn a within-subjects design, participants will take placebo, madopar, and propranolol each once in three separate sessions. |
Who may qualify
- Ages
- 25 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age 25-40 years old (including boundary value).
- Elementary school education or above, able to understand the research content.
- Body temperature, blood pressure, heart rate, respiratory rate, and electrocardiogram are all normal. Among them, the blood pressure range is 100-139/70-89 mmHg, and the heart rate range is 60-85 beats/min.
Key exclusion criteria (7 listed)
- Vulnerable groups, including people with mental illness, cognitive impairment, critically ill subjects, minors, pregnant women, illiterates, etc.
- Family history of genetic diseases.
- Major physical diseases, including cardiovascular, respiratory, digestive, renal, endocrine, blood and other systemic diseases.
- History of alcohol/drug dependence.
- Lactating women.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| single-dose madopar, single-dose propranolol, and single-dose placebo by orderParticipants will take madopar, propranolol, and placebo (orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days. | Drug | madopar-propranolol-placebo |
| single-dose madopar, single-dose placebo, and single-dose propranolol by orderParticipants will take madopar, placebo(orange juice), and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days. | Drug | madopar-placebo-propranolol |
| single-dose propranolol, single-dose madopar, and single-dose placebo by orderParticipants will take propranolol, madopar, and placebo(orange juice) each once in three separate sessions. The interval between every two sessions will be at least 3 days. | Drug | propranolol-madopar-placebo |
| single-dose propranolol, single-dose placebo, and single-dose madopar by orderParticipants will take propranolol, placebo(orange juice), and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days. | Drug | propranolol-placebo-madopar |
| single-dose placebo, single-dose propranolol, and single-dose madopar by orderParticipants will take placebo(orange juice), propranolol, and madopar each once in three separate sessions. The interval between every two sessions will be at least 3 days. | Drug | placebo-propranolol-madopar |
| single-dose placebo, single-dose madopar, and single-dose propranolol by orderParticipants will take placebo(orange juice), madopar, and propranolol each once in three separate sessions. The interval between every two sessions will be at least 3 days. | Drug | placebo-madopar-propranolol |
Primary outcome
Choices to invest or not in the investment task
Time frame: between 1-2 hours after taking the drugs or the placebo
Participants decide whether or not to accept investment options that entail a 50/50 chance of winning some amount of money and losing some amount of money.
Response times to invest or not in the investment task
Time frame: between 1-2 hours after taking the drugs or the placebo
Participants decide whether or not to accept investment options that entail a 50/50 chance of winning some amount of money and losing some amount of money.
Choices to turn or not in the driving task
Time frame: between 1-2 hours after taking the drugs or the placebo
Participants decide whether or not to make turns during driving in order to sacrifice some number of person(s) to save some number of person(s) .
Response times to turn or not in the driving task
Time frame: between 1-2 hours after taking the drugs or the placebo
Participants decide whether or not to make turns during driving in order to sacrifice some number of person(s) to save some number of person(s) .
Choices to buy or sell in the trading task
Time frame: between 1-2 hours after taking the drugs or the placebo
Participants decide whether or not to buy or sell a product at certain prices.
Response times to buy or sell in the trading task
Time frame: between 1-2 hours after taking the drugs or the placebo
Participants decide whether or not to buy or sell a product at certain prices.
Reported outcomes in die task
Time frame: between 1-2 hours after taking the drugs or the placebo
Participants report the outcome for each throw of the die.
1 secondary outcome
Affects
Time frame: before and 1 hour after taking the drugs or the placebo
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Sep 2023.
- Background: PubMed 32385152Sheng F, Ramakrishnan A, Seok D, Zhao WJ, Thelaus S, Cen P, Platt ML. Decomposing loss aversion from gaze allocation and pupil dilation. Proc Natl Acad Sci U S A. 2020 May 26;117(21):11356-11363. doi: 10.1073/pnas.1919670117. Epub 2020 May 8.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Healthy, run by Sir Run Run Shaw Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Choices to invest or not in the investment task (time frame: between 1-2 hours after taking the drugs or the placebo). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06034158, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2023.